Civic Intelligence

The Adenoid Cystic Carcinoma Research

EIN 20-6745475 • 501(c)3 • Needham, MA

Profile

The adenoid cystic carcinoma research foundation (accrf) supports research into adenoid cystic carcinoma that will accelerate the development of improved therapies and a cure for the disease.

PO Box 442Needham, MA 02494

www.accrf.org

Siviq Scores

Precomputed percentiles relative to similar nonprofits. These scores are descriptive rather than judgmental.

Liabilities / Assets

32nd percentile

0.01x

Higher debt load relative to assets than 32% of similar nonprofits.

501(c)3 • $1M-$5M nonprofits • Source year 2024

Liabilities / Revenue

34th percentile

0.02x

Higher debt load relative to revenue than 34% of similar nonprofits.

501(c)3 • $1M-$5M nonprofits • Source year 2024

Net Margin

11th percentile

-27%

Higher net margin than 11% of similar nonprofits.

501(c)3 • $1M-$5M nonprofits • Source year 2024

Top Officer Pay

82nd percentile

$150,000

Higher top officer pay than 82% of similar nonprofits.

Top officer pay equals 13.1% of source-year revenue.

501(c)3 • $1M-$5M nonprofits • Source year 2024

Asset Growth

12th percentile

-16%

Faster asset growth than 12% of similar nonprofits.

501(c)3 • $1M-$5M nonprofits • Annualized from 2023 to 2024

Revenue Growth

8th percentile

-39%

Faster revenue growth than 8% of similar nonprofits.

501(c)3 • $1M-$5M nonprofits • Annualized from 2023 to 2024

Assets

Down

$2,251,893

Down $438,877 (-16%) from 2023

Liabilities

Down

$20,252

Down $126,874 (-86%) from 2023

Net Assets

Down

$2,231,641

Down $312,003 (-12%) from 2023

Revenue

Down

$1,146,195

Down $747,350 (-39%) from 2023

Expenses

Down

$1,458,198

Down $414,522 (-22%) from 2023

Net Income

Down

-$312,003

Down $332,828 (-1598%) from 2023

Trend Graphs

Balance Sheet Trend

Grouped bars show assets, liabilities, and net assets across loaded filings.

$4.0M$3.0M$2.0M$1.0M$0Assets 2012: $2,848,746Liabilities 2012: $121,802Net Assets 2012: $2,726,9442012Assets 2013: $2,149,665Liabilities 2013: $553,087Net Assets 2013: $1,596,5782013Assets 2014: $2,054,654Liabilities 2014: $606,809Net Assets 2014: $1,447,8452014Assets 2015: $2,146,242Liabilities 2015: $826,387Net Assets 2015: $1,319,8552015Assets 2016: $1,563,125Liabilities 2016: $1,245,381Net Assets 2016: $317,7442016Assets 2017: $1,623,360Liabilities 2017: $867,661Net Assets 2017: $755,6992017Assets 2018: $1,935,482Liabilities 2018: $431,090Net Assets 2018: $1,504,3922018Assets 2019: $2,646,923Liabilities 2019: $264,728Net Assets 2019: $2,382,1952019Assets 2020: $2,608,038Liabilities 2020: $438,388Net Assets 2020: $2,169,6502020Assets 2021: $3,133,519Liabilities 2021: $607,759Net Assets 2021: $2,525,7602021Assets 2022: $2,659,707Liabilities 2022: $136,888Net Assets 2022: $2,522,8192022Assets 2023: $2,690,770Liabilities 2023: $147,126Net Assets 2023: $2,543,6442023Assets 2024: $2,251,893Liabilities 2024: $20,252Net Assets 2024: $2,231,6412024

Highlighted filing

2024

Assets$2,251,893
Liabilities$20,252
Net Assets$2,231,641

Operations Trend

Revenue, expenses, and net income by year, with the latest filing highlighted.

$3.0M$2.0M$1.0M$0-$1.0M-$2.0MRevenue 2012: $1,692,225Expenses 2012: $1,377,751Net Income 2012: $314,4742012Revenue 2013: $765,063Expenses 2013: $1,895,429Net Income 2013: -$1,130,3662013Revenue 2014: $1,376,304Expenses 2014: $1,525,037Net Income 2014: -$148,7332014Revenue 2015: $1,671,328Expenses 2015: $1,799,318Net Income 2015: -$127,9902015Revenue 2016: $1,099,873Expenses 2016: $2,101,984Net Income 2016: -$1,002,1112016Revenue 2017: $1,602,683Expenses 2017: $1,164,728Net Income 2017: $437,9552017Revenue 2018: $2,043,147Expenses 2018: $1,294,454Net Income 2018: $748,6932018Revenue 2019: $2,103,655Expenses 2019: $1,225,852Net Income 2019: $877,8032019Revenue 2020: $1,208,448Expenses 2020: $1,420,993Net Income 2020: -$212,5452020Revenue 2021: $2,427,133Expenses 2021: $2,071,023Net Income 2021: $356,1102021Revenue 2022: $1,386,655Expenses 2022: $1,618,196Net Income 2022: -$231,5412022Revenue 2023: $1,893,545Expenses 2023: $1,872,720Net Income 2023: $20,8252023Revenue 2024: $1,146,195Expenses 2024: $1,458,198Net Income 2024: -$312,0032024

Highlighted filing

2024

Revenue$1,146,195
Expenses$1,458,198
Net Income-$312,003

Filings

Latest Filing Detail
Jump To
Filing Snapshot
Filing Period
Jan 1, 2024 to Dec 31, 2024
Signed
May 12, 2025
Return Version
2024v5.1
Gross Receipts
$1,146,195
Mission and Program Overview

Mission

The adenoid cystic carcinoma research foundation (accrf) supports research into adenoid cystic carcinoma that will accelerate the development of improved therapies and a cure for the disease.

Supporting research into the treatment and cure of adenoid cystic carcinoma.

Balance Sheet Detail
LineBeginningEndChange
Assets
Savings and Temporary Cash Investments$2,067,028$2,183,175▲ $116,147
Cash and Non-Interest-Bearing Accounts$79,075$47,328▼ $31,747
Accounts Receivable$523,646$21,300▼ $502,346
Prepaid Expenses and Deferred Charges$21,021$90▼ $20,931
Total Assets$2,690,770$2,251,893▼ $438,877
Liabilities
Grants Payable$50,000$0▼ $50,000
Accounts Payable and Accrued Expenses$78,026$20,252▼ $57,774
Deferred Revenue$19,100$0▼ $19,100
Total Liabilities$147,126$20,252▼ $126,874
Net Assets / Fund Balance
Net Assets Without Donor Restrictions$2,543,644$2,231,641▼ $312,003
Total Net Assets Fund Balance$2,543,644$2,231,641▼ $312,003
Total Liabilities and Net Assets / Fund Balance$2,690,770$2,251,893▼ $438,877
Compensation and Service Providers

Employees

NameTitleFull / Part TimeBaseTotal
Jeffrey a KaufmanExecutive Director/board CFT$150,000$150,000
Nicole Spardy BurrDirector of ResearchFT$142,500$142,500

Board Members and Trustees

NameTitle
Thomas DilengeBoard Vice Chair
Bozho TodorichDirector
David MorseDirector
Elizabeth WehlageDirector
Emma KinlochDirector
Marnie a KaufmanDirector & CFO
Ralph MollisTreasurer
Revenue and Support

Revenue Composition

Contributions and Grants
$654,137
Program Service Revenue
$395,168
Investment Income
$96,890
Other Revenue
$0
All Other Contributions
$654,137
Change in Net Assets
$-312,003

Audited Revenue Reconciliation

Revenue per Audited Statements
$1,146,195
Revenue Not Reported on Financial Statements
$0
Revenue Not Reported on Form 990
$37,500
Total Revenue per Audited Statements
$1,183,695
Total Revenue per Form 990
$1,146,195
Expenses and Functional Allocation

Major Expense Lines

Line ItemAmount
Other Expenses$572,816
Grants and Similar Amounts Paid$464,311
Salaries, Compensation, and Employee Benefits$421,071
Total Fundraising Expense$64,763
Professional Fundraising Fees$0

Functional Expense Allocation

Line ItemProgramManagementFundraisingTotal
Grants to Domestic Orgs$367,325--$367,325
Other Salaries and Wages$148,764$58,568$34,222$241,554
Current Officers, Directors, Trustees, and Key Employees$92,379$36,369$21,252$150,000
Foreign Grants$96,986--$96,986
Office Expenses$36,620$5,154$3,349$45,123
Payroll Taxes$18,178$7,157$4,182$29,517
Fees for Services Accounting-$19,204-$19,204
Conferences and Meetings$12,193--$12,193
Fees for Services Other-$2,566$1,758$4,324
Other Expenses$1,499--$1,499
Insurance$521--$521
Total Functional Expenses$1,264,417$129,018$64,763$1,458,198

Audited Expense Reconciliation

Line ItemAmount
Total Expenses per Audited Statements$1,495,698
Expenses per Audited Statements$1,458,198
Total Expenses per Form 990$1,458,198
Expenses Not Reported on Form 990$37,500
Expenses Not Reported on Financial Statements$0
International Activity

Grant and Assistance Recipients

RecipientLocationCategoryPurposeAmount
Mission Viejo Hospital and UclaMission Viejo, CA501(c)(3)CT-GUIDED LDR BRACHYTHERAPY FOR ADENOID CYSTIC CARCINOMA LUNG METASTASES: EFFICACY AND SAFETY OUTCOMES.$100,000
Dana Farber Cancer InstituteBoston, MA501(c)(3)STEREOTACTIC BODY RADIOTHERAPY (SBRT) FOR EARLY TREATMENT OF OLIGOMETASTATIC ADENOID CYSTIC CARCINOMA: THE SOLAR TRIAL$50,000
Mass GeneralBoston, MA501(c)(3)Chemical Proteomics to Target Myb in Acc$50,000
Md Anderson Cancer CenterHouston, TX501(c)(3)Vegfr Inhibitors in Adenoid Cystic Carcinoma$50,000
H Lee Moffitt Cancer Center & Research Institute IncTampa, FL501(c)(3)Molecular Characterization of the Salivary Adenoid Cystic Carcinoma Tumor Immune Landscape by Anatomic Subsite$49,999
Virgina Commonwealth University of MedicineRichmond, VA501(c)(3)To Study the Expression of Flower-win and Flower-lose in Adenoid Cystic Carcinoma (acc)$49,989
Baylor College of MedicineHouston, TX501(c)(3)Adenoid Cystic Carcinoma Arising at Non-salivary Sites in the U.s.- a Proposal for Analysis of Two National Cancer Datasets.$36,768
Rutgers Cancer InstituteNew Brunswick, NJ501(c)(3)Patterns of Care in the Management of Patients With Adenoid Cystic Carcinoma of the Breast$30,569

International Summary

Offices
0
Employees
0
Spending
$96,986

International Compliance

Foreign grant records maintained
No
Activity in boycott countries
No
Foreign corporation ownership
No
Foreign partnership interest
No
Interest in foreign trust
No
Passive foreign investment company interest
No
Transfers to foreign corporations
No

International Activities

RegionActivityServicesOfficesEmployeesSpending
Europe (including Iceland & Greenland)Grants to Recipients Located in Region.Multicenter Validation of P63 Immunohistochemistry (ihc) as a Prognostic Marker for Adenoid Cystic Carcinoma (instituto Portugus De Oncologia De Lisboa) (radbound University, Netherlands & Instituto Portugues De Oncologia Delisboa, Portugal) and Identifying Novel Treatment Options as Well as Predictive Biomarkers for Existing Immune Therapies in Advanced Acc (charite Comprehensive Cancer Center, Germany)00$72,013
East Asia and the PacificGrants to Recipients Located in Region.A Prelude Towards Transforming Adenoid Cystic Carcinoma Into an Immune Hot Tumour (macquarie University, Australia)00$24,973
Fundraising, Events, and Gaming
Fundraising activities
No
Gaming activities
No
Professional fundraiser used
No

Fundraising and Gaming Totals

Line ItemAmount
Professional Fundraising Fees$0
Political and Lobbying Activity
Political campaign activity
No
Lobbying activity
No
Subject to proxy tax
No
Governance and Compliance

Governance Checklist

Compiled or reviewed by an accountant
No
Annual disclosure for covered persons
Yes
Audit committee
Yes
Backup withholding compliance
Yes
Business relationship with 35% controlled entity
No
Business relationship with family members
No
Business relationship with organization members
No
Material changes to governing documents
No
Compensation from other sources disclosed
No
CEO compensation reviewed
Yes
Other officer compensation reviewed
No
Conflict-of-interest policy
Yes
Audited financial statements prepared
No
Key decisions subject to board approval
No
Management duties delegated
No

Governance Explanations

Form 990, Part VI, Section A, Line 2

The executive director, jeffrey a. Kaufman, is married to a director on the board, marnie a. Kaufman.

Form 990, Part VI, Section B, Line 11B

The form 990 is prepared by the external auditors and reviewed by management. Once all are satisfied with the form, it is finalized and a copy is sent to all directors. The directors are asked if they have any questions or comments and a general review of the form is conducted by management . Revisions and corrections are made as necessary. Subsequently, the form is submitted to the irs.

Form 990, Part VI, Section B, Line 12C

A formal process is undertaken each year to monitor and enforce the conflict of interest policy contained within the bylaws . Each january, an annual survey on conflicts of interest is completed by every director and officer covering the prior calendar year. All business relationships, if any, are reported to the board of directors. Excluding any interested parties, a majority of remaining directors determines whether a conflict of interest has occurred and whether a more advantageous transaction is available to the foundation that would not lead to a conflict of interest. The board is charged with taking appropriate disciplinary and corrective action in the case of a violation of the conflict of interest policy.

Form 990, Part VI, Section B, Line 15A

A formal strategic review, objective setting and performance review process is undertaken each year. The board of directors reviews the performance of the organization and executive director, based on goals and objectives previously agreed upon during the prior calendar year and on a performance report submitted by the executive director in advance. The independent directors of the board meet separately to assess the executive director's performance, agree on a process to inform the executive director of any areas of needed improvement, and agree upon a merit and/or cost of living salary increase for the director , subject to availability of funds and maintenance of an appropriate ratio between such salary and accrf fundraising/revenue totals in any given year . The board of directors sets performance objectives and metrics for the organization and the executive director for the current calendar year.

Form 990, Part VI, Section C, Line 19

The organization makes its governing documents (articles of incorporation and by-laws}, its conflict of interest policy and financial statements available upon request. The organization will mail copies upon request or provide copies to those who come to the administrative offices during normal business hours.

Filing and Contact Details

Filer

Filer Name
The Adenoid Cystic Carcinoma Research
EIN
20-6745475
Phone
7812489699
Address
PO BOX 442, NEEDHAM, MA 02494

Signing Officer

Name
Jeffrey a Kaufman
Title
Executive Director
Phone
7812489699
Signed
2025-05-12
Discuss with paid preparer
Yes

Organization Details

Principal Officer
Jeffrey a Kaufman
Formed
2005
Legal Domicile
Ma
Voting Board Members
8
Independent Board Members
6
Employees
3
Volunteers
7

Preparer

Firm
Cbiz Advisors LLC
Address
53 STATE STREET, BOSTON, MA 02109
Preparer
Kristen Cummings
Phone
6178075000
Supplemental Narrative

Financial Statement Notes

PART X, LINE 2:

The foundation is exempt from income taxes as a public charity under section 501(c)(3) of the internal revenue code. Management believes that the foundation operates in a manner consistent with their tax-exempt status at both the state and federal level. The foundation annually files irs form 990 - return of organization exempt from income tax, reporting various information that the irs uses to monitor the activities of tax-exempt entities. These tax returns are subject to review by the taxing authorities generally for a period of three years after they were filed. The foundation currently has no tax examinations in progress. The foundation evaluates all significant tax positions. As of december 31, 2024, the foundation does not believe that it has taken any tax positions that would require the recording of any additional tax liability nor does it believe that there are any unrealized tax benefits that would either increase or decrease within the next 12 months. The foundation did not pay any interest or penalties in 2024.

Raw XML AppendixShowing 400 of 552 raw XML fields

This appendix keeps the raw XML leaves available for debugging and edge-case review. The human report above is the primary experience.

Path#Value
IRS990/AccountantCompileOrReviewInd00
IRS990/AccountsPayableAccrExpnssGrp/BOYAmt078026
IRS990/AccountsPayableAccrExpnssGrp/EOYAmt020252
IRS990/AccountsReceivableGrp/BOYAmt0523646
IRS990/AccountsReceivableGrp/EOYAmt021300
IRS990/ActivitiesConductedPrtshpInd00
IRS990/ActivityOrMissionDesc0SUPPORTING RESEARCH INTO THE TREATMENT AND CURE OF ADENOID CYSTIC CARCINOMA.
IRS990/AllOtherContributionsAmt0654137
IRS990/AnnualDisclosureCoveredPrsnInd01
IRS990/AuditCommitteeInd01
IRS990/BackupWthldComplianceInd01
IRS990/BooksInCareOfDetail/BusinessName/BusinessNameLine1Txt0MARNIE A KAUFMAN
IRS990/BooksInCareOfDetail/PhoneNum07814491757
IRS990/BooksInCareOfDetail/USAddress/AddressLine1Txt060 SAVOY ROAD
IRS990/BooksInCareOfDetail/USAddress/CityNm0NEEDHAM
IRS990/BooksInCareOfDetail/USAddress/StateAbbreviationCd0MA
IRS990/BooksInCareOfDetail/USAddress/ZIPCd002492
IRS990/BusinessRlnWith35CtrlEntInd00
IRS990/BusinessRlnWithFamMemInd00
IRS990/BusinessRlnWithOrgMemInd00
IRS990/CashNonInterestBearingGrp/BOYAmt079075
IRS990/CashNonInterestBearingGrp/EOYAmt047328
IRS990/ChangeToOrgDocumentsInd00
IRS990/CntrctRcvdGreaterThan100KCnt00
IRS990/CollectionsOfArtInd00
IRS990/CompCurrentOfcrDirectorsGrp/FundraisingAmt021252
IRS990/CompCurrentOfcrDirectorsGrp/ManagementAndGeneralAmt036369
IRS990/CompCurrentOfcrDirectorsGrp/ProgramServicesAmt092379
IRS990/CompCurrentOfcrDirectorsGrp/TotalAmt0150000
IRS990/CompensationFromOtherSrcsInd00
IRS990/CompensationProcessCEOInd01
IRS990/CompensationProcessOtherInd00
IRS990/ConferencesMeetingsGrp/ProgramServicesAmt012193
IRS990/ConferencesMeetingsGrp/TotalAmt012193
IRS990/ConflictOfInterestPolicyInd01
IRS990/ConservationEasementsInd00
IRS990/ConsolidatedAuditFinclStmtInd00
IRS990/CreditCounselingInd00
IRS990/CYBenefitsPaidToMembersAmt00
IRS990/CYContributionsGrantsAmt0654137
IRS990/CYGrantsAndSimilarPaidAmt0464311
IRS990/CYInvestmentIncomeAmt096890
IRS990/CYOtherExpensesAmt0572816
IRS990/CYOtherRevenueAmt00
IRS990/CYProgramServiceRevenueAmt0395168
IRS990/CYRevenuesLessExpensesAmt0-312003
IRS990/CYSalariesCompEmpBnftPaidAmt0421071
IRS990/CYTotalExpensesAmt01458198
IRS990/CYTotalFundraisingExpenseAmt064763
IRS990/CYTotalProfFndrsngExpnsAmt00
IRS990/CYTotalRevenueAmt01146195
IRS990/DecisionsSubjectToApprovaInd00
IRS990/DeductibleArtContributionInd00
IRS990/DeductibleNonCashContriInd00
IRS990/DeferredRevenueGrp/BOYAmt019100
IRS990/DeferredRevenueGrp/EOYAmt00
IRS990/DelegationOfMgmtDutiesInd00
IRS990/Desc0TRANSLATION TO THE CLINIC: ACCRF SUPPORTS AND COORDINATES RESEARCH INTO TREATMENTS MOST LIKELY TO LEAD TO CLINICAL EBENFIT FOR ADENOID CYSTIC CARCINOMA PATIENTS. DRUG DISCOVERY, DRUG DEVELOPMENT, PRECLINICAL DRUG SCREENING AND CORRELATIVE STUDIES ARE CRUCIAL TO THE INITIATION AND OPTIMAL CONDUCT OF CLINICAL TRIALS.
IRS990/DescribedInSection501c3Ind01
IRS990/DisregardedEntityInd00
IRS990/DocumentRetentionPolicyInd01
IRS990/DonorAdvisedFundInd00
IRS990/DonorRstrOrQuasiEndowmentsInd00
IRS990/ElectionOfBoardMembersInd00
IRS990/EmployeeCnt03
IRS990/EmploymentTaxReturnsFiledInd01
IRS990/EngagedInExcessBenefitTransInd00
IRS990/ExpenseAmt0787961
IRS990/FamilyOrBusinessRlnInd01
IRS990/FederalGrantAuditRequiredInd00
IRS990/FeesForServicesAccountingGrp/ManagementAndGeneralAmt019204
IRS990/FeesForServicesAccountingGrp/TotalAmt019204
IRS990/FeesForServicesOtherGrp/FundraisingAmt01758
IRS990/FeesForServicesOtherGrp/ManagementAndGeneralAmt02566
IRS990/FeesForServicesOtherGrp/TotalAmt04324
IRS990/ForeignActivitiesInd01
IRS990/ForeignFinancialAccountInd00
IRS990/ForeignGrantsGrp/ProgramServicesAmt096986
IRS990/ForeignGrantsGrp/TotalAmt096986
IRS990/ForeignOfficeInd00
IRS990/Form8282PropertyDisposedOfInd00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt050.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt15.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt25.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt335.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt45.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt55.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt65.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt75.00
IRS990/Form990PartVIISectionAGrp/AverageHoursPerWeekRt840.00
IRS990/Form990PartVIISectionAGrp/HighestCompensatedEmployeeInd0X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd0X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd1X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd2X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd3X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd4X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd5X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd6X
IRS990/Form990PartVIISectionAGrp/IndividualTrusteeOrDirectorInd7X
IRS990/Form990PartVIISectionAGrp/OfficerInd0X
IRS990/Form990PartVIISectionAGrp/OfficerInd1X
IRS990/Form990PartVIISectionAGrp/OfficerInd2X
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt00
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt10
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt20
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt30
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt40
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt50
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt60
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt70
IRS990/Form990PartVIISectionAGrp/OtherCompensationAmt80
IRS990/Form990PartVIISectionAGrp/PersonNm0JEFFREY A KAUFMAN
IRS990/Form990PartVIISectionAGrp/PersonNm1THOMAS DILENGE
IRS990/Form990PartVIISectionAGrp/PersonNm2RALPH MOLLIS
IRS990/Form990PartVIISectionAGrp/PersonNm3MARNIE A KAUFMAN
IRS990/Form990PartVIISectionAGrp/PersonNm4ELIZABETH WEHLAGE
IRS990/Form990PartVIISectionAGrp/PersonNm5DAVID MORSE
IRS990/Form990PartVIISectionAGrp/PersonNm6BOZHO TODORICH
IRS990/Form990PartVIISectionAGrp/PersonNm7EMMA KINLOCH
IRS990/Form990PartVIISectionAGrp/PersonNm8NICOLE SPARDY BURR
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt0150000
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt10
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt20
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt30
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt40
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt50
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt60
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt70
IRS990/Form990PartVIISectionAGrp/ReportableCompFromOrgAmt8142500
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt00
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt10
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt20
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt30
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt40
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt50
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt60
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt70
IRS990/Form990PartVIISectionAGrp/ReportableCompFromRltdOrgAmt80
IRS990/Form990PartVIISectionAGrp/TitleTxt0EXECUTIVE DIRECTOR/BOARD C
IRS990/Form990PartVIISectionAGrp/TitleTxt1BOARD VICE CHAIR
IRS990/Form990PartVIISectionAGrp/TitleTxt2TREASURER
IRS990/Form990PartVIISectionAGrp/TitleTxt3DIRECTOR & CFO
IRS990/Form990PartVIISectionAGrp/TitleTxt4DIRECTOR
IRS990/Form990PartVIISectionAGrp/TitleTxt5DIRECTOR
IRS990/Form990PartVIISectionAGrp/TitleTxt6DIRECTOR
IRS990/Form990PartVIISectionAGrp/TitleTxt7DIRECTOR
IRS990/Form990PartVIISectionAGrp/TitleTxt8DIRECTOR OF RESEARCH
IRS990/Form990ProvidedToGvrnBodyInd01
IRS990/FormationYr02005
IRS990/FormerOfcrEmployeesListedInd00
IRS990/FSAuditedBasisGrp/SeparateBasisFinclStmtInd0X
IRS990/FSAuditedInd01
IRS990/FundraisingActivitiesInd00
IRS990/GamingActivitiesInd00
IRS990/GoverningBodyVotingMembersCnt08
IRS990/GrantAmt0289350
IRS990/GrantsPayableGrp/BOYAmt050000
IRS990/GrantsPayableGrp/EOYAmt00
IRS990/GrantsToDomesticOrgsGrp/ProgramServicesAmt0367325
IRS990/GrantsToDomesticOrgsGrp/TotalAmt0367325
IRS990/GrantsToIndividualsInd00
IRS990/GrantsToOrganizationsInd01
IRS990/GrantToRelatedPersonInd00
IRS990/GrossReceiptsAmt01146195
IRS990/GroupReturnForAffiliatesInd00
IRS990/IncludeFIN48FootnoteInd01
IRS990/IndependentAuditFinclStmtInd01
IRS990/IndependentVotingMemberCnt06
IRS990/IndivRcvdGreaterThan100KCnt02
IRS990/IndoorTanningServicesInd00
IRS990/InfoInScheduleOPartVIInd0X
IRS990/InsuranceGrp/ProgramServicesAmt0521
IRS990/InsuranceGrp/TotalAmt0521
IRS990/InvestmentIncomeGrp/ExclusionAmt096890
IRS990/InvestmentIncomeGrp/TotalRevenueColumnAmt096890
IRS990/InvestmentInJointVentureInd00
IRS990/IRPDocumentCnt01
IRS990/IRPDocumentW2GCnt00
IRS990/LegalDomicileStateCd0MA
IRS990/LoanOutstandingInd00
IRS990/LobbyingActivitiesInd00
IRS990/LocalChaptersInd00
IRS990/MaterialDiversionOrMisuseInd00
IRS990/MembersOrStockholdersInd00
IRS990/MethodOfAccountingAccrualInd0X
IRS990/MinutesOfCommitteesInd01
IRS990/MinutesOfGoverningBodyInd01
IRS990/MissionDesc0THE ADENOID CYSTIC CARCINOMA RESEARCH FOUNDATION (ACCRF) SUPPORTS RESEARCH INTO ADENOID CYSTIC CARCINOMA THAT WILL ACCELERATE THE DEVELOPMENT OF IMPROVED THERAPIES AND A CURE FOR THE DISEASE.
IRS990/MoreThan5000KToIndividualsInd00
IRS990/MoreThan5000KToOrgInd01
IRS990/NetAssetsOrFundBalancesBOYAmt02543644
IRS990/NetAssetsOrFundBalancesEOYAmt02231641
IRS990/NetUnrelatedBusTxblIncmAmt00
IRS990/NoDonorRestrictionNetAssetsGrp/BOYAmt02543644
IRS990/NoDonorRestrictionNetAssetsGrp/EOYAmt02231641
IRS990/NondeductibleContributionsInd00
IRS990/OfficeExpensesGrp/FundraisingAmt03349
IRS990/OfficeExpensesGrp/ManagementAndGeneralAmt05154
IRS990/OfficeExpensesGrp/ProgramServicesAmt036620
IRS990/OfficeExpensesGrp/TotalAmt045123
IRS990/OfficerMailingAddressInd00
IRS990/OperateHospitalInd00
IRS990/Organization501c3Ind0X
IRS990/OrganizationFollowsFASB117Ind0X
IRS990/OtherChangesInNetAssetsAmt00
IRS990/OtherExpensesGrp/Desc0RESEARCH STUDIES EXPENS
IRS990/OtherExpensesGrp/Desc1DRUG SCREENING EXPENSE
IRS990/OtherExpensesGrp/Desc2STATE REGISTRATION AND
IRS990/OtherExpensesGrp/Desc3OTHER FEES
IRS990/OtherExpensesGrp/ProgramServicesAmt0283148
IRS990/OtherExpensesGrp/ProgramServicesAmt1204639
IRS990/OtherExpensesGrp/ProgramServicesAmt22165
IRS990/OtherExpensesGrp/ProgramServicesAmt31499
IRS990/OtherExpensesGrp/TotalAmt0283148
IRS990/OtherExpensesGrp/TotalAmt1204639
IRS990/OtherExpensesGrp/TotalAmt22165
IRS990/OtherExpensesGrp/TotalAmt31499
IRS990/OtherSalariesAndWagesGrp/FundraisingAmt034222
IRS990/OtherSalariesAndWagesGrp/ManagementAndGeneralAmt058568
IRS990/OtherSalariesAndWagesGrp/ProgramServicesAmt0148764
IRS990/OtherSalariesAndWagesGrp/TotalAmt0241554
IRS990/PartialLiquidationInd00
IRS990/PayPremiumsPrsnlBnftCntrctInd00
IRS990/PayrollTaxesGrp/FundraisingAmt04182
IRS990/PayrollTaxesGrp/ManagementAndGeneralAmt07157
IRS990/PayrollTaxesGrp/ProgramServicesAmt018178
IRS990/PayrollTaxesGrp/TotalAmt029517
IRS990/PoliticalCampaignActyInd00
IRS990/PrepaidExpensesDefrdChargesGrp/BOYAmt021021
IRS990/PrepaidExpensesDefrdChargesGrp/EOYAmt090
IRS990/PrincipalOfficerNm0JEFFREY A KAUFMAN
IRS990/ProfessionalFundraisingInd00
IRS990/ProgramServiceRevenueGrp/BusinessCd0621500
IRS990/ProgramServiceRevenueGrp/Desc0RESEARCH STUDIES
IRS990/ProgramServiceRevenueGrp/RelatedOrExemptFuncIncomeAmt0395168
IRS990/ProgramServiceRevenueGrp/TotalRevenueColumnAmt0395168
IRS990/ProgSrvcAccomActy2Grp/Desc0BASIC RESEARCH: ACCRF SUPPORTS AND COORDINATES THE DESCRIPTIVE AND FUNCTIONAL STUDIES THAT IDENTIFY MOLECULAR TARGETS AND PATHWAYS THAT PERMIT ADENOID CYSTIC CARCINOMA TO PROGRESS. BY FOCUSING ON THE MECHANISMS OF ACTION, RESEARCHERS MAY DISCOVER MORE QUICKLY THE ACHILLES' HEEL OF THE DISEASE.
IRS990/ProgSrvcAccomActy2Grp/ExpenseAmt0476456
IRS990/ProgSrvcAccomActy2Grp/GrantAmt0174961
IRS990/ProgSrvcAccomActy2Grp/RevenueAmt00
IRS990/ProhibitedTaxShelterTransInd00
IRS990/PYBenefitsPaidToMembersAmt00
IRS990/PYContributionsGrantsAmt0748287
IRS990/PYExcessBenefitTransInd00
IRS990/PYGrantsAndSimilarPaidAmt0225883
IRS990/PYInvestmentIncomeAmt090836
IRS990/PYOtherExpensesAmt01255566
IRS990/PYOtherRevenueAmt00
IRS990/PYProgramServiceRevenueAmt01054422
IRS990/PYRevenuesLessExpensesAmt020825
IRS990/PYSalariesCompEmpBnftPaidAmt0391271
IRS990/PYTotalExpensesAmt01872720
IRS990/PYTotalProfFndrsngExpnsAmt00
IRS990/PYTotalRevenueAmt01893545
IRS990/QuidProQuoContributionsInd00
IRS990/RcvFndsToPayPrsnlBnftCntrctInd00
IRS990/ReconcilationRevenueExpnssAmt0-312003
IRS990/RegularMonitoringEnfrcInd01
IRS990/RelatedEntityInd00
IRS990/RelatedOrganizationCtrlEntInd00
IRS990/ReportInvestmentsOtherSecInd00
IRS990/ReportLandBuildingEquipmentInd00
IRS990/ReportOtherAssetsInd00
IRS990/ReportOtherLiabilitiesInd00
IRS990/ReportProgramRelatedInvstInd00
IRS990/RevenueAmt0395168
IRS990/SavingsAndTempCashInvstGrp/BOYAmt02067028
IRS990/SavingsAndTempCashInvstGrp/EOYAmt02183175
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearAmt0654139
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus1YearAmt0748287
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus2YearsAmt0807996
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus3YearsAmt01588834
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus4YearsAmt0787706
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/TotalAmt04586962
IRS990ScheduleA/GrossInvestmentIncome170Grp/CurrentTaxYearAmt096890
IRS990ScheduleA/GrossInvestmentIncome170Grp/CurrentTaxYearMinus1YearAmt090836
IRS990ScheduleA/GrossInvestmentIncome170Grp/CurrentTaxYearMinus2YearsAmt030851
IRS990ScheduleA/GrossInvestmentIncome170Grp/CurrentTaxYearMinus3YearsAmt0403
IRS990ScheduleA/GrossInvestmentIncome170Grp/CurrentTaxYearMinus4YearsAmt010071
IRS990ScheduleA/GrossInvestmentIncome170Grp/TotalAmt0229051
IRS990ScheduleA/GrossReceiptsRltdActivitiesAmt03249233
IRS990ScheduleA/PublicOrganization170Ind0X
IRS990ScheduleA/PublicSupportCY170Pct00.70700
IRS990ScheduleA/PublicSupportPY170Pct00.77020
IRS990ScheduleA/PublicSupportTotal170Amt03405006
IRS990ScheduleA/SubstantialContributorsTotAmt01181956
IRS990ScheduleA/ThirtyThrPctSuprtTestsCY170Ind0X
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearAmt0654139
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus1YearAmt0748287
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus2YearsAmt0807996
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus3YearsAmt01588834
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus4YearsAmt0787706
IRS990ScheduleA/TotalCalendarYear170Grp/TotalAmt04586962
IRS990ScheduleA/TotalSupportAmt04816013
IRS990ScheduleB/ContributorInformationGrp/ContributorBusinessName/BusinessNameLine10RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorNum0RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/AddressLine10RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/AddressLine20RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/City0RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/State0RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/ContributorUSAddress/ZIPCode0RESTRICTED
IRS990ScheduleB/ContributorInformationGrp/TotalContributionsAmt0RESTRICTED
IRS990/ScheduleBRequiredInd01
IRS990ScheduleD/DonatedServicesAndUseFcltsAmt037500
IRS990ScheduleD/DonatedServicesUseFcltsAmt037500
IRS990ScheduleD/ExpensesNotReportedAmt037500
IRS990ScheduleD/ExpensesNotRptFinclStmtAmt00
IRS990ScheduleD/ExpensesSubtotalAmt01458198
IRS990ScheduleD/FootnoteTextInd0X
IRS990ScheduleD/RevenueNotReportedAmt037500
IRS990ScheduleD/RevenueNotReportedFinclStmtAmt00
IRS990ScheduleD/RevenueSubtotalAmt01146195
IRS990ScheduleD/SupplementalInformationDetail/ExplanationTxt0THE FOUNDATION IS EXEMPT FROM INCOME TAXES AS A PUBLIC CHARITY UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE. MANAGEMENT BELIEVES THAT THE FOUNDATION OPERATES IN A MANNER CONSISTENT WITH THEIR TAX-EXEMPT STATUS AT BOTH THE STATE AND FEDERAL LEVEL. THE FOUNDATION ANNUALLY FILES IRS FORM 990 - RETURN OF ORGANIZATION EXEMPT FROM INCOME TAX, REPORTING VARIOUS INFORMATION THAT THE IRS USES TO MONITOR THE ACTIVITIES OF TAX-EXEMPT ENTITIES. THESE TAX RETURNS ARE SUBJECT TO REVIEW BY THE TAXING AUTHORITIES GENERALLY FOR A PERIOD OF THREE YEARS AFTER THEY WERE FILED. THE FOUNDATION CURRENTLY HAS NO TAX EXAMINATIONS IN PROGRESS. THE FOUNDATION EVALUATES ALL SIGNIFICANT TAX POSITIONS. AS OF DECEMBER 31, 2024, THE FOUNDATION DOES NOT BELIEVE THAT IT HAS TAKEN ANY TAX POSITIONS THAT WOULD REQUIRE THE RECORDING OF ANY ADDITIONAL TAX LIABILITY NOR DOES IT BELIEVE THAT THERE ARE ANY UNREALIZED TAX BENEFITS THAT WOULD EITHER INCREASE OR DECREASE WITHIN THE NEXT 12 MONTHS. THE FOUNDATION DID NOT PAY ANY INTEREST OR PENALTIES IN 2024.
IRS990ScheduleD/SupplementalInformationDetail/FormAndLineReferenceDesc0PART X, LINE 2:
IRS990ScheduleD/TotalBookValueLandBuildingsAmt00
IRS990ScheduleD/TotalExpensesPerForm990Amt01458198
IRS990ScheduleD/TotalRevenuePerForm990Amt01146195
IRS990ScheduleD/TotalRevEtcAuditedFinclStmtAmt01183695
IRS990ScheduleD/TotExpnsEtcAuditedFinclStmtAmt01495698
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/EmployeeCnt00
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/EmployeeCnt10
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/OfficesCnt00
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/OfficesCnt10
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/RegionTotalExpendituresAmt072013
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/RegionTotalExpendituresAmt124973
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/RegionTxt0EUROPE (INCLUDING ICELAND & GREENLAND)
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/RegionTxt1EAST ASIA AND THE PACIFIC
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/SpecificServicesProvidedTxt0MULTICENTER VALIDATION OF P63 IMMUNOHISTOCHEMISTRY (IHC) AS A PROGNOSTIC MARKER FOR ADENOID CYSTIC CARCINOMA (INSTITUTO PORTUGUS DE ONCOLOGIA DE LISBOA) (RADBOUND UNIVERSITY, NETHERLANDS & INSTITUTO PORTUGUES DE ONCOLOGIA DELISBOA, PORTUGAL) AND IDENTIFYING NOVEL TREATMENT OPTIONS AS WELL AS PREDICTIVE BIOMARKERS FOR EXISTING IMMUNE THERAPIES IN ADVANCED ACC (CHARITE COMPREHENSIVE CANCER CENTER, GERMANY)
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/SpecificServicesProvidedTxt1A PRELUDE TOWARDS TRANSFORMING ADENOID CYSTIC CARCINOMA INTO AN IMMUNE HOT TUMOUR (MACQUARIE UNIVERSITY, AUSTRALIA)
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/TypeOfActivitiesConductedTxt0GRANTS TO RECIPIENTS LOCATED IN REGION.
IRS990ScheduleF/AccountActivitiesOutsideUSGrp/TypeOfActivitiesConductedTxt1GRANTS TO RECIPIENTS LOCATED IN REGION.
IRS990ScheduleF/BoycottCountriesInd00
IRS990ScheduleF/ContinuationSpentAmt00
IRS990ScheduleF/ContinuationTotalEmployeeCnt00
IRS990ScheduleF/ContinuationTotalOfficeCnt00
IRS990ScheduleF/ForeignCorpOwnershipInd00
IRS990ScheduleF/ForeignPartnershipInd00
IRS990ScheduleF/GrantRecordsMaintainedInd00
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/CashGrantAmt043800
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/CashGrantAmt125000
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/CashGrantAmt224973
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/MannerOfCashDisbursementTxt0CHECK OR FUND TRANSFER
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/MannerOfCashDisbursementTxt1CHECK OR FUND TRANSFER
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/MannerOfCashDisbursementTxt2CHECK OR FUND TRANSFER
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/NonCashAssistanceAmt00
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/NonCashAssistanceAmt10
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/NonCashAssistanceAmt20
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/PurposeOfGrantTxt0IDENTIFYING NOVEL TREATMENT OPTIONS AS WELL AS PREDICTIVE BIOMARKERS FOR EXISTING IMMUNE THERAPIES IN ADVANCED ACC. (CHARITE COMPREHENSIVE CANCER CENTER)
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/PurposeOfGrantTxt1MULTICENTER VALIDATION OF P63 IMMUNOHISTOCHEMISTRY (IHC) AS A PROGNOSTIC MARKER FOR ADENOID CYSTIC CARCINOMA (RADBOUD)
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/PurposeOfGrantTxt2A PRELUDE TOWARDS TRANSFORMING ADENOID CYSTIC CARCINOMA INTO AN IMMUNE HOT TUMOUR. (MACQUARIE UNIVERSITY)
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/RegionTxt0GERMANY
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/RegionTxt1NETHERLANDS
IRS990ScheduleF/GrantsToOrgOutsideUSGrp/RegionTxt2AUSTRALIA
IRS990ScheduleF/InterestInForeignTrustInd00
IRS990ScheduleF/PassiveForeignInvestmestCoInd00
IRS990ScheduleF/SubtotalEmployeesCnt00
IRS990ScheduleF/SubtotalOfficesCnt00
IRS990ScheduleF/SubtotalSpentAmt096986
IRS990ScheduleF/SupplementalInformationDetail/ExplanationTxt0ALL FOREIGN GRANTS ARE MADE TO MAJOR RESEARCH INSTITUTIONS OR HOSPITALS WITH INTERNATIONAL REPUTATIONS. IN ADDITION TO INTERIM WRITTEN REPORTS ON RESEARCH PROJECTS AND A FINAL REPORT FOLLOWING PROJECT COMPLETION, ACCRF ANNUALLY MEETS WITH EACH OF THE FOREIGN GRANTEES TO RECEIVE AN ORAL REPORT ON THE RESEARCH PROJECTS.
IRS990ScheduleF/SupplementalInformationDetail/FormAndLineReferenceDesc0PART I, LINE 2:
IRS990ScheduleF/TotalEmployeeCnt00
IRS990ScheduleF/TotalOfficeCnt00
IRS990ScheduleF/TotalSpentAmt096986
IRS990ScheduleF/TransferToForeignCorpInd00
IRS990ScheduleI/GrantRecordsMaintainedInd01
IRS990ScheduleI/RecipientTable/CashGrantAmt036768
IRS990ScheduleI/RecipientTable/CashGrantAmt1100000
IRS990ScheduleI/RecipientTable/CashGrantAmt250000
IRS990ScheduleI/RecipientTable/CashGrantAmt349989
IRS990ScheduleI/RecipientTable/CashGrantAmt450000
IRS990ScheduleI/RecipientTable/CashGrantAmt549999
IRS990ScheduleI/RecipientTable/CashGrantAmt650000
IRS990ScheduleI/RecipientTable/CashGrantAmt730569
IRS990ScheduleI/RecipientTable/IRCSectionDesc0501(C)(3)
IRS990ScheduleI/RecipientTable/IRCSectionDesc1501(C)(3)
IRS990ScheduleI/RecipientTable/IRCSectionDesc2501(C)(3)
IRS990ScheduleI/RecipientTable/IRCSectionDesc3501(C)(3)
IRS990ScheduleI/RecipientTable/IRCSectionDesc4501(C)(3)
IRS990ScheduleI/RecipientTable/IRCSectionDesc5501(C)(3)
IRS990ScheduleI/RecipientTable/IRCSectionDesc6501(C)(3)
IRS990ScheduleI/RecipientTable/IRCSectionDesc7501(C)(3)
IRS990ScheduleI/RecipientTable/NonCashAssistanceAmt00
IRS990ScheduleI/RecipientTable/NonCashAssistanceAmt10
IRS990ScheduleI/RecipientTable/NonCashAssistanceAmt20
IRS990ScheduleI/RecipientTable/NonCashAssistanceAmt30
IRS990ScheduleI/RecipientTable/NonCashAssistanceAmt40
IRS990ScheduleI/RecipientTable/NonCashAssistanceAmt50
IRS990ScheduleI/RecipientTable/NonCashAssistanceAmt60
IRS990ScheduleI/RecipientTable/NonCashAssistanceAmt70
IRS990ScheduleI/RecipientTable/PurposeOfGrantTxt0ADENOID CYSTIC CARCINOMA ARISING AT NON-SALIVARY SITES IN THE U.S.- A PROPOSAL FOR ANALYSIS OF TWO NATIONAL CANCER DATASETS.
IRS990ScheduleI/RecipientTable/PurposeOfGrantTxt1CT-GUIDED LDR BRACHYTHERAPY FOR ADENOID CYSTIC CARCINOMA LUNG METASTASES: EFFICACY AND SAFETY OUTCOMES.
IRS990ScheduleI/RecipientTable/PurposeOfGrantTxt2STEREOTACTIC BODY RADIOTHERAPY (SBRT) FOR EARLY TREATMENT OF OLIGOMETASTATIC ADENOID CYSTIC CARCINOMA: THE SOLAR TRIAL
IRS990ScheduleI/RecipientTable/PurposeOfGrantTxt3TO STUDY THE EXPRESSION OF FLOWER-WIN AND FLOWER-LOSE IN ADENOID CYSTIC CARCINOMA (ACC)
IRS990ScheduleI/RecipientTable/PurposeOfGrantTxt4VEGFR INHIBITORS IN ADENOID CYSTIC CARCINOMA
IRS990ScheduleI/RecipientTable/PurposeOfGrantTxt5MOLECULAR CHARACTERIZATION OF THE SALIVARY ADENOID CYSTIC CARCINOMA TUMOR IMMUNE LANDSCAPE BY ANATOMIC SUBSITE
IRS990ScheduleI/RecipientTable/PurposeOfGrantTxt6CHEMICAL PROTEOMICS TO TARGET MYB IN ACC
IRS990ScheduleI/RecipientTable/PurposeOfGrantTxt7PATTERNS OF CARE IN THE MANAGEMENT OF PATIENTS WITH ADENOID CYSTIC CARCINOMA OF THE BREAST
IRS990ScheduleI/RecipientTable/RecipientBusinessName/BusinessNameLine1Txt0BAYLOR COLLEGE OF MEDICINE
IRS990ScheduleI/RecipientTable/RecipientBusinessName/BusinessNameLine1Txt1MISSION VIEJO HOSPITAL AND UCLA
IRS990ScheduleI/RecipientTable/RecipientBusinessName/BusinessNameLine1Txt2DANA FARBER CANCER INSTITUTE

Document Assets

No mirrored PDF or thumbnail assets are attached yet.